Akero Therapeutics Inc AKRO
$54.65 $0.10 (0.18%) 1D
Last Updated: Dec 08, 12:00 AM·BE
Pricing for DE stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
Is Akero Therapeutics Inc Stock Halal?
Shariah Compliance Analysis of AKRO Stock
Germany Health Care Mid Cap No. As of September 2026, Akero Therapeutics Inc (AKRO) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Akero Therapeutics Inc does not pass Musaffa's business and financial screening criteria.
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The company is headquartered in South San Francisco, California and currently employs 67 full-time employees. The company went IPO on 2019-06-20. Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
AKRO Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, Akero Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Akero Therapeutics Inc (AKRO) Chart
Financial Metrics & Statements of Akero Therapeutics Inc (AKRO)
FAQ's for Akero Therapeutics Inc (AKRO)
- As of September 2026, Akero Therapeutics Inc AKRO is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Akero Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Akero Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Akero Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Akero Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Akero Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Akero Therapeutics Inc (AKRO)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
